SCYNEXIS, Inc. reported a net loss of $5.4 million, or $0.11 basic loss per share, for the first quarter ended March 31, 2025, on May 15, 2025. The company's revenue for the quarter was $0.26 million.
A significant development was the lifting of the clinical hold by the FDA on the ibrexafungerp MARIO study. However, SCYNEXIS is working to resolve a disagreement with GSK regarding milestone payments associated with the restart of the MARIO study.
In a positive development, Hansoh Pharma recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. This approval will trigger a milestone payment from Hansoh to SCYNEXIS, along with royalties of approximately 10% on China sales.
The company also presented positive preclinical data for its second-generation fungerp, SCY-247, and continues to advance its development program. SCYNEXIS's cash, cash equivalents, and investments totaled $75.1 million as of December 31, 2024, providing a cash runway into Q3 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.